Welcome to our dedicated page for Orthopedia news (Ticker: KIDS), a resource for investors and traders seeking the latest updates and insights on Orthopedia stock.
OrthoPediatrics Corp. (NASDAQ: KIDS) is an orthopedic medical device company focused exclusively on pediatric orthopedics, and its news flow reflects this specialization. Company announcements frequently cover revenue updates, financial guidance, and quarterly earnings, where OrthoPediatrics discusses performance across its trauma and deformity, scoliosis, and specialty bracing (OPSB) product lines, as well as metrics such as the number of children treated with its systems.
Readers following KIDS news can expect regular updates on financial results and outlook, including preliminary unaudited revenue releases, full quarterly earnings reports, and adjustments to annual guidance. These releases often highlight contributions from specific product categories, trends in domestic and international revenue, and management’s commentary on operational initiatives such as restructuring efforts and cost management.
OrthoPediatrics also issues news on product development and regulatory milestones. Recent examples include FDA approval of the 3P Pediatric Plating Platform Small-Mini System, additional FDA clearances within a single year, and EUMDR certification for spine, trauma, and deformity implants and instruments. The company reports on first clinical procedures with new systems, such as the VerteGlide Spinal Growth Guidance System for early onset scoliosis, and on portfolio expansions like new PediHip bracing products within OPSB.
In addition, KIDS news includes strategic and corporate updates, such as distribution partnerships (for example, with MY01 for Continuous Perfusion Sensing Technology), expansion of OPSB clinics and territories, participation in healthcare and investor conferences, and changes to the board of directors. Investors and observers who monitor this news stream gain insight into how OrthoPediatrics is evolving its pediatric orthopedic platform, broadening its product offering, and engaging with clinicians and the capital markets.
OrthoPediatrics Corp. (KIDS) announced the expansion of its Specialty Bracing (OPSB) division into three new markets in Indiana, Colorado, and Florida. The OPSB division, launched in early 2024, aims to increase pediatric care access through new clinics and strategic acquisitions.
The company opened a new clinic in Indianapolis near Riley Children's Hospital and Peyton Manning Children's Hospital, established a new site within Nationwide Children's Hospital in Columbus, OH, acquired a clinic group in Colorado with plans for Denver area expansion, and acquired a clinic in Davie, Florida, serving as a foundation for statewide growth.
This expansion is part of OPSB's multi-year strategy to enhance access to non-operative pediatric orthopedic solutions through both greenfield clinics and strategic acquisitions, focusing on partnerships with pediatric orthopedic surgeons across different regions.
OrthoPediatrics Corp. (Nasdaq: KIDS) has expanded its Specialty Bracing portfolio with two new products: the OPSB Sensor System and MOVE-D™. The OPSB Sensor System is the company's first sensor solution, featuring Bluetooth connectivity that uploads wear-time data to an interactive app with gamification elements and cloud-based storage for healthcare provider monitoring. The MOVE-D™, acquired through license and distribution agreements with Innovation Lab, is a mechanical elbow brace designed to stabilize tremors in the dominant upper extremity for pediatric patients with movement disorders, improving daily activities performance.
The company's subsidiary, Boston Orthotics & Prosthetics, has been using thermal sensors in scoliosis braces for over 10 years, based on research showing correlation between brace wear time and treatment success.
OrthoPediatrics (Nasdaq: KIDS) announced its participation and Emerald-Level sponsorship at the 20th Annual International Pediatric Orthopaedic Symposium (IPOS) in Orlando, Florida, from December 3-7. The event, expecting over 500 pediatric orthopedic surgeons, will feature the company's exhibition booths showcasing their full product suite, including the new Enabling Technology division with 7D, 3-D Side, and Specialty Bracing division (OPSB).
The company will host several educational sessions, including discussions on rigid tibial nailing, bioresorbable implants, career launching, and spica cast usage. A pre-course innovation session focusing on creative solutions is also scheduled.
OrthoPediatrics (Nasdaq: KIDS) announces significant updates to its DF2® Brace, expanding its applications and market reach. The brace, previously used for femur fracture fixation, now includes post-operative stabilization indications. The company has expanded sizing options from XS to XXL and launched the product in Europe, Middle East, and Asia-Pacific markets. The DF2 Brace serves as an alternative to traditional spica casting for pediatric patients aged 6 months to 5 years, providing immobilization of the femur, knee, and hip. This expansion demonstrates OrthoPediatrics' commitment to improving pediatric orthopedic care globally.
OrthoPediatrics (Nasdaq: KIDS), a company dedicated to pediatric orthopedics, has announced its participation in two upcoming investor conferences in New York. Dave Bailey, President & Chief Executive Officer, will participate in fireside chats at the Stifel 2024 Healthcare Conference on November 19, 2024, at 10:55 am ET, and the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024, at 9:00 am ET. Audio webcasts of both discussions will be available on the company's investor relations website, with replays accessible after the events.
OrthoPediatrics (KIDS) reported record Q3 2024 financial results with total revenue of $54.6 million, up 37% year-over-year. U.S. revenue increased 45% to $42.7 million, while international revenue grew 12% to $11.9 million. The company helped over 33,000 children, a 50% increase from Q3 2023. Trauma & Deformity revenue grew 31%, Scoliosis revenue increased 52%, and Sports Medicine revenue rose 50%. Despite strong revenue growth, the company reported a net loss of $7.9 million. OrthoPediatrics increased its full-year 2024 revenue guidance to $202-204 million, representing 36-37% growth compared to 2023.
OrthoPediatrics Corp. (NASDAQ: KIDS) has launched its Enabling Technologies division, aimed at expanding into digital health and advanced technology within pediatric orthopedics. Led by Kevin Unger, this division builds on the company's existing innovations like the 7D Flash™ Navigation System and partnership with 3D Side, S.A. for patient-specific cutting guides.
Two new platforms are set to launch:
- Playbook: A surgical workflow and outcome optimization platform
- Robotic-Assistance for Cochlear Implant Technology: Developed in partnership with iotaMotion, Inc.
CEO David Bailey emphasized that this division will help impact more children and provide long-term growth opportunities. The company is hosting an Investor Day on September 12, 2024, to discuss these developments further.
OrthoPediatrics Corp. (Nasdaq: KIDS), a company dedicated to advancing pediatric orthopedics, has announced an upcoming investor day on September 12, 2024, in New York City. The event, starting at 10:30 AM ET, will provide important updates on the company's:
- Specialty Bracing business strategy
- Product pipeline
- Financial outlook
A key feature of the event will be a KOL surgeon panel. Investors interested in attending can register by contacting the investor relations department at hannah@gilmartinir.com by September 6, 2024. For those unable to attend in person, a live webcast will be available, with a recording accessible later on the company's investor relations website.
OrthoPediatrics Corp. (Nasdaq: KIDS) reported strong Q2 2024 financial results, with record revenue of $52.8 million, up 33% year-over-year. The company helped a record 32,000 children, a 52% increase from Q2 2023. Domestic revenue grew 39% to $41.2 million, while international revenue increased 16% to $11.6 million. Trauma & Deformity revenue rose 37%, Scoliosis revenue grew 26%, and Sports Medicine/Other revenue increased 17%.
The company reaffirmed its full-year 2024 revenue guidance of $200.0-$203.0 million, representing 34-36% growth. OrthoPediatrics also announced a financing agreement with Braidwell, LP for up to $100 million in capital, strengthening its balance sheet.
OrthoPediatrics Corp. (NASDAQ: KIDS) has secured a private financing arrangement with Braidwell LP, providing up to $100 million in capital. The deal includes a $50 million term loan and $50 million in convertible notes. The term loan has an interest rate of SOFR + 6.50%, while the convertible notes accrue interest at 4.75% annually. The notes are convertible into common stock at $40.98 per share, a 30% premium to recent trading prices.
The company plans to use the funds to repay existing debt, cover transaction fees, and support general corporate purposes. Additionally, OrthoPediatrics' Board has approved a $5 million stock repurchase program. This financing is expected to strengthen the company's balance sheet and provide flexibility for strategic growth initiatives, particularly in expanding OPSB clinics at children's hospitals nationwide.
FAQ
What is the current stock price of Orthopedia (KIDS)?
What is the market cap of Orthopedia (KIDS)?
